Brust- und gynäkologische Tumoren – medikamentöse Therapie ossärer Metastasen: Teil 1

Der Knochen stellt einen häufigen Metastasierungsort solider Tumoren dar. Knochenmetastasen treten insbesondere bei Karzinomen der Mamma, der Prostata, der Niere sowie der Lunge auf [1] und können starke Schmerzen sowie skelettbezogene Komplikationen verursachen, die zu einer erhöhten Mortalität und Morbidität sowie einer erheblichen Beeinträchtigung der Lebensqualität führen.

Schlüsselwörter

Knochenschmerz - tumorinduzierte Hyperkalzämie - ossäre Metastasierung - skelettale Komplikationen

• Literatur

• 1 Huang JF, Shen J, Li X. et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Ann Transl Med 2020; 8: 482
• 2 Reddington JA, Mendez GA, Ching A. et al. Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic. Surg Neurol Int 2016; 7 (Suppl. 13) S361-S365
• 3 Wedam SB, Beaver JA, Amiri-Kordestani L. et al. US Food and Drug Administration pooled analysis to assess the impact of bone-only metastatic breast cancer on clinical trial outcomes and radiographic assessments. J Clin Oncol 2018; 36: 1225-1231
• 4 Kuris EO, McDonald CL, Palumbo MA. et al. Evaluation and management of cauda equina syndrome. Am J Med 2021; 134: 1483-1489
• 5 Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF. Leitlinienprogramm Onkologie. Supportive Therapie bei onkologischen PatientInnen – Langversion 1.3, AWMF Registernummer: 032/054OL. 2020 Accessed November 30, 2022 at: https://register.awmf.org/de/leitlinien/detail/032–054OL
• 6 Conti A, Acker G, Kluge A. et al. Decision making in patients with metastatic spine. The role of minimally invasive treatment modalities. Front Oncol 2019; 9: 915
• 7 Reimer T, Solomayer E-F. AGO e. V.. Osteoonkologie und Knochengesundheit. 2022 Accessed November 30, 2022 at: https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2022/Einzeldateien/AGO_2022D_20_Osteoonkologie_und_Knochengesundheit.pdf
• 8 Greco MT, Roberto A, Corli O. et al. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol 2014; 32: 4149-4154
• 9 Laird BJA, Walley J, Murray GD. et al. Characterization of cancer-induced bone pain: an exploratory study. Support Care Cancer 2011; 19: 1393-1401
• 10 Fallon M, Giusti R, Aielli F. et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29 (Suppl. 04) iv166-iv191
• 11 Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69: 1-18
• 12 Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol 2014; 32: 1647-1654
• 13 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.2. AWMF-Registernummer: 128/001OL. 2020 Accessed November 30, 2022 at: https://register.awmf.org/de/leitlinien/detail/128–001OL
• 14 WHO. WHO Guidelines for the pharmacological and radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: World Health Organization; 2018
• 15 Derry S, Wiffen PJ, Moore RA. et al. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev 2017; (07) CD012638
• 16 Wiffen PJ, Derry S, Moore RA. et al. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev 2017; (07) CD012637
• 17 Gaertner J, Stamer UM, Remi C. et al. Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice. Palliat Med 2017; 31: 26-34
• 18 Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev 2017; (05) CD012508
• 19 Bandieri E, Romero M, Ripamonti CI. et al. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 2016; 34: 436-442
• 20 Caraceni A, Hanks G, Kaasa S. et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: e58-e68
• 21 Häuser W, Petzke F, Radbruch L. Praxiswerkzeug 10 „Opioidrotation“ der 2. Aktualisierung der S3 Leitlinie Langzeitanwendungen von Opioiden bei chronischen nicht-tumorbedingten Schmerzen „LONTS“. 20.01.2020 Accessed November 30, 2022 at: https://register.awmf.org/de/leitlinien/detail/145-003
• 22 Kane CM, Mulvey MR, Wright S. et al. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis. Palliat Med 2018; 32: 276-286
• 23 Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S. et al. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project. Palliat Med 2017; 31: 5-25
• 24 O’Carrigan B, Wong MHF, Willson ML. et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2017; (10) CD003474
• 25 Cleeland CS, Body JJ, Stopeck A. et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 2013; 119: 832-838
• 26 von Moos R, Body JJ, Egerdie B. et al. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 2013; 21: 3497-3507
• 27 Chow R, Hoskin P, Hollenberg D. et al. Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis. Ann Palliat Med 2017; 6: 125-142
• 28 Guise TA, Wysolmerski JJ. Cancer-associated hypercalcemia. N Engl J Med 2022; 386: 1443-1451
• 29 Stewart AF. Hypercalcemia associated with cancer. N Engl J Med 2005; 352: 373-379
• 30 Goldner W. Cancer-related hypercalcemia. J Oncol Pract 2016; 12: 426-432
• 31 Major P, Lortholary A, Hon J. et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19: 558-567
• 32 Nussbaum SR, Younger J, Vandepol CJ. et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-,60-, and 90-mg dosages. Am J Med 1993; 95: 297-304
• 33 Gucalp R, Theriault R, Gill I. et al. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 1994; 154: 1935-1944
• 34 Pecherstorfer M, Steinhauer EU, Rizzoli R. et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 2003; 11: 539-547
• 35 Panpharma GmbH. Fachinformation Calcitonin PANPHARMA 100 I.E./1 ml Injektionslösung. Trittau: Panpharma GmbH; 2020: 1